PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.
http://www.peervoice.com
Eine durchschnittliche Folge dieses Podcasts dauert 19m.
Bisher sind 228 Folge(n) erschienen.
Dieser Podcast erscheint alle 9 Tage.
Gesamtlänge aller Episoden: 3 days 15 hours 1 minute
Second-Line Therapies for EGFR Wild-Type NSCLC: What Is the Best Treatment? That Is the Question!
Go online to www.peervoice.com/h/pve44 to view the entire programme with slides.
Improving Outcomes in Cystic Fibrosis: Novel Strategies and Adherence
Improving Outcomes in Cystic Fibrosis: Novel Strategies and Adherence
PARPs in Practice in mCRPC: A Look at the Latest Data
PARPs in Practice in mCRPC: A Look at the Latest Data
State of the Science in CKD: New Treatment, New Outcomes
State of the Science in CKD: New Treatment, New Outcomes
Practicalities in the Management of Hypertrophic Cardiomyopathy: A Case-Based Approach
Practicalities in the Management of Hypertrophic Cardiomyopathy: A Case-Based Approach
Taking the Sting Out of Hyperkalaemia: What Clinicians Can Do Now
Taking the Sting Out of Hyperkalaemia: What Clinicians Can Do Now
Treatment Update in Type 2 Diabetes: What’s New, and What Does It Mean for Patients?
Treatment Update in Type 2 Diabetes: What’s New, and What Does It Mean for Patients?
Managing Risk of Persistent Acute Kidney Injury in the ICU: The RUBY Study
Managing Risk of Persistent Acute Kidney Injury in the ICU: The RUBY Study